Profile data is unavailable for this security.
About the company
InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing a pipeline of prescription-based products, including rare cannabinoids and cannabinoid analogs, targeting the treatment of diseases with high unmet medical needs, as well as developing proprietary manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its segments include InMed Pharmaceuticals and BayMedica. The InMed Pharmaceuticals segment is engaged in research and development of cannabinoid-based pharmaceutical products. The BayMedica segment is focused on developing manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its two product candidates include INM-755 and INM-088. INM-755 is developed as a topical skin cream formulation containing cannabinol (CBN) for the treatment of symptoms related to Epidermolysis Bullosa (EB). INM-088 is used for the treatment of glaucoma.
- Revenue in USD (TTM)5.63m
- Net income in USD-6.08m
- Incorporated1981
- Employees13.00
- LocationInMed Pharmaceuticals IncSUITE 310, 815 W. HASTINGS STREETVANCOUVER V6C 1B4CanadaCAN
- Phone+1 (604) 669-7207
- Fax+1 (778) 945-6800
- Websitehttps://www.inmedpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novelstem International Corp | 15.00k | -4.22m | 3.37m | 15.00 | -- | -- | -- | 224.72 | -0.09 | -0.09 | 0.0003 | -0.0478 | 0.0065 | -- | 10.00 | -- | -172.16 | -- | -1,011.77 | -- | -- | -- | -26,418.53 | -- | -- | -8.40 | 2.34 | -- | 0.00 | -- | -446.84 | -- | -- | -- |
Aridis Pharmaceuticals Inc | 22.36m | -1.14m | 3.41m | 37.00 | -- | -- | -- | 0.1525 | -0.1845 | -0.1845 | 0.7074 | -0.2648 | 2.40 | -- | 58.45 | 604,297.30 | -12.24 | -120.16 | -- | -678.29 | -- | -- | -5.11 | -1,559.63 | -- | -- | -- | -- | 101.37 | 29.16 | 34.43 | -- | -34.84 | -- |
Ensysce Biosciences Inc | 1.75m | -11.55m | 3.49m | 7.00 | -- | 0.8993 | -- | 2.00 | -3.74 | -3.74 | 0.5109 | 0.5115 | 0.3886 | -- | 9.06 | 249,514.30 | -257.00 | -17.68 | -574.02 | -19.42 | -- | -- | -661.34 | -715.78 | -- | -6.25 | 0.0671 | -- | -11.61 | -- | 57.64 | -- | -- | -- |
Lipella Pharmaceuticals Inc | 477.45k | -4.74m | 3.50m | 5.00 | -- | 1.26 | -- | 7.33 | -0.7633 | -0.7633 | 0.0747 | 0.3638 | 0.1232 | -- | 6.25 | 95,490.00 | -122.37 | -- | -146.33 | -- | -- | -- | -993.39 | -- | -- | -- | 0.00 | -- | 144.15 | -- | -77.81 | -- | -- | -- |
OpGen Inc | 3.42m | -32.67m | 3.59m | 100.00 | -- | -- | -- | 1.05 | -40.91 | -40.91 | 4.35 | -9.01 | 0.2469 | 5.22 | 11.07 | -- | -235.91 | -87.95 | -1,149.98 | -127.65 | -2.65 | 15.42 | -955.69 | -794.78 | 0.1383 | -8.17 | -- | -- | 31.11 | 3.02 | 12.38 | -- | 40.20 | -- |
InMed Pharmaceuticals Inc | 5.63m | -6.08m | 3.72m | 13.00 | -- | 0.1503 | -- | 0.6609 | -1.23 | -1.23 | 0.9284 | 1.75 | 0.4006 | 2.71 | 29.77 | -- | -43.26 | -88.10 | -50.03 | -104.19 | 39.20 | -- | -108.01 | -1,066.11 | 5.80 | -- | 0.00 | -- | 279.60 | -- | 57.27 | -- | 29.56 | -- |
Protagenic Therapeutics Inc | 0.00 | -6.01m | 3.78m | 1.00 | -- | 1.77 | -- | -- | -1.37 | -1.37 | 0.00 | 0.4808 | 0.00 | -- | -- | 0.00 | -117.26 | -74.49 | -140.56 | -92.56 | -- | -- | -- | -- | -- | -11.50 | 0.00 | -- | -- | -- | -40.64 | -- | -- | -- |
CTT Pharmaceutical Holdings Inc | 0.00 | -1.67m | 3.80m | 0.00 | -- | 2.14 | -- | -- | -0.0822 | -0.0822 | 0.00 | 0.0346 | 0.00 | -- | -- | -- | -317.28 | 13.49 | -448.83 | 304.48 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3,454.52 | -- | -- | -- |
CERo Therapeutics Holdings Inc | 0.00 | -2.54m | 3.83m | 8.00 | -- | -- | -- | -- | -0.3796 | -0.3796 | 0.00 | -0.9226 | 0.00 | -- | -- | 0.00 | -9.96 | -- | -33.80 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -279.82 | -- | -- | -- |
Mosaic Immunoengineering Inc | 0.00 | -897.69k | 3.86m | 3.00 | -- | -- | -- | -- | -0.1245 | -0.1245 | 0.00 | -0.8498 | 0.00 | -- | -- | 0.00 | -789.46 | -- | -- | -- | -- | -- | -- | -- | -- | -26.91 | -- | -- | -- | -- | 57.65 | -- | -- | -- |
ProtoKinetix, Inc. | 0.00 | -400.47k | 3.88m | 0.00 | -- | 9.79 | -- | -- | -0.0012 | -0.0012 | 0.00 | 0.0011 | 0.00 | -- | -- | -- | -88.14 | -696.88 | -101.62 | -785.51 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 78.22 | -- | 10.78 | -- |
Enveric Biosciences Inc | 0.00 | -15.11m | 3.95m | 7.00 | -- | 0.5739 | -- | -- | -6.46 | -6.46 | 0.00 | 0.8887 | 0.00 | -- | -- | 0.00 | -122.02 | -104.94 | -178.49 | -156.88 | -- | -- | -- | -243.54 | -- | -- | 0.00 | -- | -- | -- | 7.14 | -- | -- | -- |
Trevena Inc | 3.14m | -40.15m | 3.97m | 23.00 | -- | -- | -- | 1.27 | -2.71 | -2.71 | 0.2107 | -0.7999 | 0.0904 | -- | -- | 136,478.30 | -115.65 | -55.93 | -148.14 | -66.35 | 48.04 | -- | -1,279.01 | -3,134.41 | -- | -15.39 | 1.88 | -- | 847.61 | -11.43 | 24.93 | -- | -24.67 | -- |
Genprex Inc | 0.00 | -27.63m | 3.99m | 26.00 | -- | 0.4172 | -- | -- | -19.18 | -19.18 | 0.00 | 4.55 | 0.00 | -- | -- | 0.00 | -153.97 | -92.06 | -202.83 | -98.32 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -29.99 | -- | -7.13 | -- |
Axim Biotechnologies Inc | 85.35k | -5.59m | 4.05m | 6.00 | -- | -- | -- | 47.47 | -0.0249 | -0.0249 | 0.0003 | -0.0268 | 0.0214 | -- | -- | 14,225.00 | -140.13 | -154.34 | -- | -390.73 | -- | -- | -6,548.75 | -36,362.71 | -- | -1.16 | -- | -- | 345.05 | -27.38 | -29.10 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Sabby Management LLCas of 31 Mar 2024 | 361.73k | 4.33% |
Armistice Capital LLCas of 31 Mar 2024 | 266.97k | 3.19% |
Renaissance Technologies LLCas of 31 Mar 2024 | 28.30k | 0.34% |
Two Sigma Securities LLCas of 31 Mar 2024 | 15.42k | 0.19% |
Citadel Securities LLCas of 31 Mar 2024 | 12.73k | 0.15% |
Qube Research & Technologies Ltd.as of 31 Mar 2024 | 200.00 | 0.00% |
BFSG LLCas of 31 Mar 2024 | 200.00 | 0.00% |
BofA Securities, Inc.as of 31 Mar 2024 | 100.00 | 0.00% |
AdvisorNet Financial, Inc.as of 31 Mar 2024 | 80.00 | 0.00% |
UBS Securities LLCas of 31 Mar 2024 | 41.00 | 0.00% |